What is the appropriate management of acute pulmonary embolism?

Treatment for Pulmonary Embolism

Initiate anticoagulation immediately without delay in all patients with suspected PE while diagnostic workup is in progress, and stratify treatment based on hemodynamic stability—use systemic thrombolysis for high-risk PE with hemodynamic instability, and prefer NOACs over warfarin for intermediate- and low-risk PE. 1

Risk-Stratified Treatment Approach

The management of acute PE fundamentally depends on the presence or absence of hemodynamic instability (sustained hypotension, shock, or cardiac arrest). This determines whether the patient has high-risk PE requiring immediate reperfusion therapy versus intermediate- or low-risk PE managed primarily with anticoagulation.

High-Risk PE (Hemodynamically Unstable)

For patients presenting with hemodynamic instability:

• Immediate anticoagulation with unfractionated heparin (UFH) including a weight-adjusted bolus injection (Class I, Level C) 1
• Systemic thrombolytic therapy is the first-line reperfusion treatment (Class I, Level B) 1
• Surgical pulmonary embolectomy is recommended when thrombolysis is contraindicated or has failed (Class I, Level C) 1
• Percutaneous catheter-directed treatment should be considered as an alternative when thrombolysis is contraindicated or has failed (Class IIa, Level C) 1
• Vasopressor support with norepinephrine and/or dobutamine should be considered for hemodynamic support (Class IIa, Level C) 1

Critical caveat: ECMO may be considered in combination with surgical embolectomy or catheter-directed treatment for patients with refractory circulatory collapse or cardiac arrest, though this represents the most extreme scenario (Class IIb, Level C) 1. The 2026 AHA/ACC guidelines introduce enhanced clinical categories for more precise severity classification and therapeutic decision-making 2.

Intermediate- and Low-Risk PE (Hemodynamically Stable)

For the majority of PE patients without hemodynamic instability:

Anticoagulation Strategy

• Start anticoagulation immediately even while diagnostic workup is ongoing if clinical probability is high or intermediate (Class I, Level C) 1

• For parenteral anticoagulation: Prefer LMWH or fondaparinux over UFH (Class I, Level A) 1

• For oral anticoagulation: NOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) are recommended over vitamin K antagonists (VKAs) (Class I, Level A) 1

• If using a VKA, overlap with parenteral anticoagulation until INR reaches 2.5 (range 2.0-3.0) (Class I, Level A) 1

Important contraindications to NOACs 1:

• Severe renal impairment
• Pregnancy and lactation
• Antiphospholipid antibody syndrome (use VKA indefinitely in these patients)

When to Escalate Treatment

• Rescue thrombolytic therapy is recommended for patients who develop hemodynamic deterioration while on anticoagulation (Class I, Level B) 1
• Surgical embolectomy or catheter-directed treatment should be considered as alternatives to rescue thrombolysis (Class IIa, Level C) 1
• Do NOT routinely use systemic thrombolysis in intermediate- or low-risk PE (Class III, Level B) 1

The COPE study demonstrated that in-hospital mortality remains concerning at 4.0% for intermediate-risk patients and 20.3% for high-risk patients, emphasizing the importance of accurate risk stratification 3. The NEWS score may enhance risk stratification within the ESC intermediate-high and high-risk groups, with NEWS ≥7 associated with significantly higher 30-day mortality 4.

Duration of Anticoagulation

• All patients require therapeutic anticoagulation for >3 months (Class I) 1

• Discontinue after 3 months if first PE was provoked by a major transient/reversible risk factor 1

• Continue indefinitely for:

  • Recurrent VTE (at least one previous episode) not related to a major transient/reversible risk factor 1
  • Antiphospholipid antibody syndrome (use VKA, not NOAC) 1

• Reassess regularly for drug tolerance, adherence, hepatic/renal function, and bleeding risk in patients on extended anticoagulation 1

Special Populations

Pregnancy

• Use therapeutic fixed doses of LMWH based on early pregnancy weight 1
• Never use NOACs during pregnancy or lactation (Class III, Level C) 1
• Avoid spinal/epidural needle insertion within 24 hours of last LMWH dose 1
• Do not administer LMWH within 4 hours of epidural catheter removal 1

IVC Filters

• Do NOT routinely use IVC filters (Class III, Level A) 1
• Consider IVC filters only for:
  • Absolute contraindications to anticoagulation (Class IIa, Level C) 1
  • PE recurrence despite therapeutic anticoagulation (Class IIa, Level C) 1

Post-PE Follow-Up

• Routinely re-evaluate patients 3-6 months after acute PE 1, 5
• Assess for persistent dyspnea or functional limitation
• Refer symptomatic patients with mismatched perfusion defects beyond 3 months to a pulmonary hypertension/CTEPH expert center 1
• Implement integrated care models to ensure optimal transition from hospital to ambulatory care 1

Early Discharge Considerations

Carefully selected low-risk PE patients should be considered for early discharge and home treatment if proper outpatient care and anticoagulation can be provided (Class IIa, Level A) 1.

Multidisciplinary Approach

The establishment of Pulmonary Embolism Response Teams (PERTs) is encouraged for managing severe PE cases, bringing together specialists from cardiology, pulmonology, hematology, vascular medicine, intensive care, cardiothoracic surgery, and interventional radiology to enhance real-time clinical decision-making 1.